Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

This study is testing a personalized cancer vaccine — designed based on your tumor's specific mutations — combined with the immunotherapy drug durvalumab, for patients with bile duct or gallbladder cancer (biliary tract cancer) that has already been treated with standard therapy including gemcitabine, cisplatin, and an anti-PD-1 drug. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of biliary tract cancer - Your cancer was previously treated with gemcitabine, cisplatin, and an immunotherapy drug - Your tumor has at least one specific mutation that the vaccine can target (confirmed by genetic testing) - You have measurable disease visible on imaging and are willing to have a tumor biopsy - You are in good general health (ECOG 0–1) - Your weight is above 30 kg and your organ function is adequate **You may NOT be eligible if...** - You have received other investigational therapy within the past 2 weeks - You need other forms of cancer treatment while on this study - You are pregnant or breastfeeding - You have uncontrolled autoimmune disease - You have active, uncontrolled hepatitis B or C Talk to your doctor to see if this trial is right for you.